| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3332017 | Hematology/Oncology Clinics of North America | 2009 | 12 Pages |
Abstract
The management of advanced gastronintestinal stromal tumor is increasingly complex because of imatinib refractory disease. Primary resistance to imatinib is uncommon, and most patients progress after development of additional genetic changes. This article reviews management strategies including surgical approaches, local modalities for progressive liver metastases, as well as novel therapeutic agents.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Neeta Somaiah, Margaret von Mehren,